Taar1 4 for Negative Symptoms
Research payments
$3,382,698
Through program year 2025, $3,382,698 in research payments was reported against Taar1 4 for Negative Symptoms, across 685 payments.
- Paid by (largest first)
- Hoffmann-La Roche Limited; Genentech, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $2,436 | 1 |
| 2024 | Research | $228,100 | 59 |
| 2023 | Research | $1,006,307 | 188 |
| 2022 | Research | $394,404 | 84 |
| 2021 | Research | $399,989 | 79 |
| 2020 | Research | $457,363 | 100 |
| 2019 | Research | $894,099 | 174 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Robert Cotes Atlanta, GA Named on 69 payments
- Scott Bartley Dallas, TX Named on 58 payments
- Mohini Ranganathan West Haven, CT Named on 27 payments
- Armen Goenjian Long Beach, CA Named on 23 payments
- Asim Shah Houston, TX Named on 22 payments
- Olga Lapeyra North Miami, FL Named on 21 payments
- Mohd Malik Saint Louis, MO Named on 18 payments
- Lev Gertsik Glendale, CA Named on 14 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.